VectivBio_Logo_RGB_Color.png
VectivBio Announces Results of Extraordinary General Meeting
09 déc. 2022 16h01 HE | VectivBio AG
BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
16 nov. 2022 07h30 HE | VectivBio AG
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
09 nov. 2022 08h28 HE | VectivBio AG
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
03 nov. 2022 07h01 HE | VectivBio AG
-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes -First Phase 3 study to prospectively evaluate safety...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
18 oct. 2022 08h30 HE | VectivBio AG
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
13 oct. 2022 07h20 HE | VectivBio AG
BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
13 oct. 2022 07h00 HE | VectivBio AG
•  Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months •  80% of patients were clinical responders (defined as a reduction in volume of...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
12 oct. 2022 10h00 HE | VectivBio AG
BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Closing of $54 Million Aggregate Financing
29 juin 2022 07h15 HE | VectivBio AG
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
14 juin 2022 21h03 HE | VectivBio AG
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...